What non‑surgical treatments can be used to shrink uterine fibroids?

Non-Surgical Treatment for Shrinking Uterine Fibroids

For shrinking uterine fibroids non-surgically, GnRH antagonists (such as relugolix, elagolix, or linzagolix) combined with low-dose estrogen-progestin are the most effective FDA-approved medical option, significantly reducing both fibroid volume and bleeding symptoms while mitigating hypoestrogenic side effects. 1

Medical Management Algorithm

First-Line Options (Symptom Control, Minimal Shrinkage)

• Hormonal contraceptives: Estrogen-progestin oral contraceptive pills or progestin-containing IUDs reduce bleeding symptoms but do not significantly shrink fibroids 1
• Tranexamic acid: Non-hormonal option for bleeding control without fibroid size reduction 1
• NSAIDs: For pain management, no effect on fibroid size 1

Second-Line Options (Significant Fibroid Shrinkage)

GnRH Agonists and Antagonists are the most effective medical treatments for reducing fibroid volume:

• GnRH antagonists (oral: elagolix, linzagolix, relugolix): Significantly reduce tumor volume and bleeding 1
• GnRH agonists (parenteral: leuprolide acetate): Equally effective at volume reduction 1
• Critical consideration: Both cause hypoestrogenic effects (headaches, hot flushes, hypertension, bone mineral density loss) when used as monotherapy
• Solution: Combination therapy with low-dose estrogen-progestin is FDA-approved, mitigates side effects while maintaining efficacy 1
• Major limitation: Symptoms rapidly recur after cessation; fertility is suppressed during treatment 1

Selective Progesterone Receptor Modulators (SPRMs)

Ulipristal acetate (UPA) and mifepristone show strong efficacy but have significant barriers:

• Ulipristal acetate: Reduces both bleeding and bulk symptoms, can be administered intermittently allowing menstruation during breaks 1

  • Demonstrated efficacy for up to 2 years with repeated intermittent courses 2
  • Critical barrier: Reports of hepatotoxicity prevent FDA approval in the United States 1
  • Available in Europe and Canada for preoperative management 2

• Mifepristone: Effective in relieving symptoms, reducing fibroid volume, and achieving amenorrhea 2

  • Recent 2024 study showed 75% reduction in uterine volume and improved hemoglobin from 9 to 12.51 gm/dL after 6 months 3
  • Complete resolution of pelvic pain by 6 months in all patients 3
  • Not currently FDA-indicated for fibroid management 2

Minimally Invasive Non-Surgical Procedures

MR-Guided Focused Ultrasound (MRgFUS)

• Uses high-intensity ultrasound waves to thermally ablate fibroids without incisions 1
• Volume reduction: 18% decrease in fibroid diameter at 2 years 1
• Reintervention rate: 30-33% at 2 years (higher than UAE) 1
• Advantages: No incisions, decreased postprocedural pain, faster recovery than surgery 1
• Disadvantages: Longer procedure time (6.75 hours), occasionally requires 2 days 1

Radiofrequency Ablation (RFA)

• Most effective volume reduction: 70% fibroid volume reduction at 6 months 4
• Particularly effective for large or hypervascular fibroids 5
• Shorter treatment duration than other thermal methods 5

Uterine Artery Embolization (UAE)

• Volume reduction: 53-54% fibroid reduction at 6 months 4, 6
• Better symptom control and lower reintervention rate (13% at 2 years) compared to MRgFUS 1
• More established long-term data than newer thermal ablation techniques

Microwave Ablation (MWA)

• Shortest treatment duration among thermal ablation methods 5
• Broad applicability across fibroid types 5

Clinical Decision Framework

Choose based on these priorities:

1. For maximum medical shrinkage: GnRH antagonist + estrogen-progestin combination (FDA-approved, best balance of efficacy and tolerability)

2. For preoperative size reduction: Short-course GnRH agonist or antagonist (commonly used to facilitate surgery) 1

3. For maximum procedural shrinkage without surgery: Radiofrequency ablation (70% volume reduction) 4

4. For established safety profile: Uterine artery embolization (54% reduction, lower reintervention rate) 4, 1

5. For completely non-invasive approach: MRgFUS (32% reduction, but highest reintervention rate) 4, 1

Critical Caveats

• All medical therapies have rapid symptom recurrence after discontinuation 1
• Fertility suppression occurs with GnRH agents during treatment 1
• Ulipristal acetate is not available in the US due to hepatotoxicity concerns despite strong efficacy data 1
• Thermal ablation procedures require appropriate patient selection based on fibroid size, location, and number 5
• Symptom control alone (without shrinkage) may be adequate for many patients using first-line hormonal options 1

The 2024 ACR Appropriateness Criteria 1 and 2025 SOGC guideline 7 emphasize that treatment selection must account for fibroid characteristics, symptom severity, and fertility goals, with GnRH antagonists representing the strongest current medical option for actual fibroid shrinkage.